Thetis Pharmaceuticals reports the launch of a new program in cancer.
Thetis CEO Gary Mathias said, “We are targeting pancreatic, metastatic colorectal, small cell lung and ovarian cancer for clinical investigation. These are major cancers characterized by substantial tumor debris and inflammation, where existing therapies have limited efficacy.”
The company has formed a scientific advisory board with several prominent cancer researchers and industry veterans.